Guide price only. Final cost is confirmed after assessment.
uFat Regenerative Therapy is a groundbreaking advancement in regenerative medicine. At London Cartilage Clinic, we utilise this cutting-edge technique, focusing on the gentle processing of adipose tissue to preserve mesenchymal Stem Cell / Medicinal Signaling Cells, enhancing the body's natural healing process. uFat therapy stands out for its ability to maintain the integrity of adipose tissue, offering superior regenerative capabilities compared to traditional methods.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
uFat focuses on gentle adipose processing to better preserve cellular architecture and stromal vascular niches that support tissue repair.
uFat and mFat are both valuable; selection depends on tissue target, required potency, and treatment objectives.
uFat is minimally invasive and designed to deliver regenerative tissue support with less disruption than more aggressive processing techniques.
At London Cartilage Clinic, uFat is integrated into a full care plan that includes diagnosis, procedural precision, and follow-up to track clinical response.
uFat therapy differs in its focus on preserving the structural integrity and cellular composition of adipose tissue. This results in a product richer in mesenchymal Stem Cell / Medicinal Signaling Cells, offering more potent regenerative properties.
uFat therapy is effective for a variety of conditions, including osteoarthritis, tissue injuries, and in cosmetic applications for tissue regeneration and anti-aging treatments.
Recovery times for uFat therapy are typically minimal, with most patients resuming normal activities within a short period. However, the specific recovery time can vary depending on the individual case.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
MACI recovery requires nine to twelve months, but the timeline is structured in phases: patients return to seated work within two weeks, normal walking by three months, jogging from month seven, and competitive sport from month twelve.
ChondroFiller is an acellular collagen scaffold that recruits the body's own progenitor cells to repair focal cartilage defects, but only when damage is confined to a single defined area of an otherwise structurally sound joint.
Bone-on-bone ankle osteoarthritis can be treated by fusing the joint permanently or replacing it to preserve motion; the TARVA trial found both procedures produced comparable functional gains. Selection between them depends on patient factors including age, activity level, and the state of neighbouring joints.
